Therapeutic Asset Ratings

329 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Thdbh120 Obesity Disorder	Tonghua Dongbao Pharmaceutical Co.,Ltd	P2	CCC (50)
Vrb-101 Obesity Disorder	Verdiva Bio Dev Limited	P2	CCC (50)
PEG LOXENATIDE Obesity Disorder	Fudan University	P2/3	CCC (50)
Ard-101 Obesity Disorder	Aardvark Therapeutics, Inc.	P2	CCC (49)
Bimagrumab Obesity Disorder	Massachusetts General Hospital	P2	CCC (48)
Enobosarm Obesity Disorder	Veru Inc.	P2	CCC (48)
Gly-200 Obesity Disorder	Glyscend, Inc.	P2	CCC (48)
Inv-202 Obesity Disorder	Inversago Pharma Inc.	P2	CCC (48)
Mibavademab Obesity Disorder	Eli Lilly and Company	P2	CCC (48)
Nbt-Nm108 Obesity Disorder	Rutgers, The State University of New Jersey	P2	CCC (48)
Nicotine Obesity Disorder	Brown University	P2	CCC (48)
OAT KERNEL MEAL Obesity Disorder	University of Toronto	P2	CCC (48)
PYY(3-36) Obesity Disorder	University College, London	P2	CCC (48)
Vigabatrin Obesity Disorder	Washington University School of Medicine	P2	CCC (48)
vtx3232 Obesity Disorder	Zomagen Biosciences Ltd.	P2	CCC (48)
Ecnoglutide Obesity Disorder	Hangzhou Sciwind Biosciences Co., Ltd.	P1/2	CCC (48)
SACUBITRIL Obesity Disorder	University of Alabama at Birmingham	P2/3	CCC (48)
Dasatinib Obesity Disorder	Cedars-Sinai Medical Center	P2/3	CC (47)
RELEBACTAM Obesity Disorder	University of Illinois at Chicago	P4	CC (46)
10-NITRO-OLEIC ACID Obesity Disorder	University of Colorado, Denver	P2	CC (46)
Akk Obesity Disorder	Central South University	P2	CC (46)
Azelaprag Obesity Disorder	BioAge Labs, Inc.	P2	CC (46)
bi 3034701 Obesity Disorder	Boehringer Ingelheim	P2	CC (46)
Bis-Octanoyl -1,3-Butanediol Obesity Disorder	Washington University School of Medicine	P2	CC (46)
Bremelanotide Obesity Disorder	Palatin Technologies, Inc	P2	CC (46)

Showing 151 to 175 of 329 assets

PreviousPage 7 of 14Next